Publications by authors named "David Roblin"

Claim this Profile
T
The Future of Machine Learning Within Target Identification: Causality, Reversibility, and Druggability.
Jake P Taylor-King, Michael Bronstein, David Roblin

Clin Pharmacol Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing graph machine learning within drug discovery and development.
Thomas Gaudelet, Ben Day, Arian R Jamasb, Jyothish Soman, Cristian Regep, David Roblin

Brief Bioinform· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combating resistance while maintaining innovation: the future of antimicrobial stewardship.
Richard J Vickers, Matteo Bassetti, Cornelius J Clancy, Kevin W Garey, David E Greenberg, David Roblin

Future Microbiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Marina Danilenko, Elaine Stamp, Deborah D Stocken, Akhtar Husain, Monique Zangarini, David Roblin

JAMA Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
Richard J Vickers, Glenn S Tillotson, Richard Nathan, Sabine Hazan, John Pullman, David Roblin

Lancet Infect Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Amy Cranston, Deborah D Stocken, Elaine Stamp, David Roblin, Julia Hamlin

Trials· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
David Roblin, Gil Yosipovitch, Brent Boyce, John Robinson, James Sandy

Acta Derm Venereol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity.
David Roblin, Ro Wickramasinghe, Gil Yosipovitch

J Am Acad Dermatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeking validation.
David Roblin

Sci Transl Med· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational research in the pharmaceutical industry: from theory to reality.
Stefan R Sultana, David Roblin, Damian O'Connell

Drug Discov Today· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational research in the pharmaceutical industry: from bench to bedside.
Damian O'Connell, David Roblin

Drug Discov Today· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Hunter C Gillies, David Roblin, Graham Jackson

Int J Cardiol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis